ANEB
Price
$1.45
Change
+$0.03 (+2.11%)
Updated
Jun 27 closing price
Capitalization
59.98M
79 days until earnings call
GTBP
Price
$3.80
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
11.14M
Interact to see
Advertisement

ANEB vs GTBP

Header iconANEB vs GTBP Comparison
Open Charts ANEB vs GTBPBanner chart's image
Anebulo Pharmaceuticals
Price$1.45
Change+$0.03 (+2.11%)
Volume$24.51K
Capitalization59.98M
GT Biopharma
Price$3.80
Change-$0.00 (-0.00%)
Volume$430
Capitalization11.14M
ANEB vs GTBP Comparison Chart in %
Loading...
ANEB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GTBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ANEB vs. GTBP commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANEB is a Buy and GTBP is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (ANEB: $1.45 vs. GTBP: $3.80)
Brand notoriety: ANEB and GTBP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANEB: 273% vs. GTBP: 1%
Market capitalization -- ANEB: $59.98M vs. GTBP: $11.14M
ANEB [@Biotechnology] is valued at $59.98M. GTBP’s [@Biotechnology] market capitalization is $11.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANEB’s FA Score shows that 0 FA rating(s) are green whileGTBP’s FA Score has 0 green FA rating(s).

  • ANEB’s FA Score: 0 green, 5 red.
  • GTBP’s FA Score: 0 green, 5 red.
According to our system of comparison, both ANEB and GTBP are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANEB’s TA Score shows that 5 TA indicator(s) are bullish while GTBP’s TA Score has 5 bullish TA indicator(s).

  • ANEB’s TA Score: 5 bullish, 4 bearish.
  • GTBP’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both ANEB and GTBP are a good buy in the short-term.

Price Growth

ANEB (@Biotechnology) experienced а -5.84% price change this week, while GTBP (@Biotechnology) price change was +24.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

ANEB is expected to report earnings on Sep 17, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ANEB($60M) has a higher market cap than GTBP($11.1M). GTBP YTD gains are higher at: 24.590 vs. ANEB (-13.690). ANEB has higher annual earnings (EBITDA): -7.27M vs. GTBP (-12M). ANEB has more cash in the bank: 13.3M vs. GTBP (2.37M). ANEB (0) and GTBP (0) have equivalent revenues.
ANEBGTBPANEB / GTBP
Capitalization60M11.1M541%
EBITDA-7.27M-12M61%
Gain YTD-13.69024.590-56%
P/E RatioN/AN/A-
Revenue00-
Total Cash13.3M2.37M562%
Total DebtN/A0-
FUNDAMENTALS RATINGS
GTBP: Fundamental Ratings
GTBP
OUTLOOK RATING
1..100
45
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
38
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ANEBGTBP
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
Momentum
ODDS (%)
Bullish Trend 3 days ago
89%
Bullish Trend 3 days ago
85%
MACD
ODDS (%)
N/A
Bullish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 14 days ago
83%
Bullish Trend 4 days ago
85%
Declines
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 13 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ANEB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GTBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HSII44.560.50
+1.13%
Heidrick & Struggles International
SXT98.410.28
+0.29%
Sensient Technology Corp
BAH102.86-0.41
-0.40%
Booz Allen Hamilton Holding Corp
PHIO2.17-0.04
-1.81%
Phio Pharmaceuticals Corp
MAPS0.87-0.06
-6.23%
WM Technology

ANEB and

Correlation & Price change

A.I.dvisor tells us that ANEB and ABCZF have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ANEB and ABCZF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANEB
1D Price
Change %
ANEB100%
+2.11%
ABCZF - ANEB
31%
Poorly correlated
N/A
ALDX - ANEB
28%
Poorly correlated
-2.07%
GTBP - ANEB
24%
Poorly correlated
N/A
SRPT - ANEB
24%
Poorly correlated
-0.70%
RLAY - ANEB
23%
Poorly correlated
-0.60%
More

GTBP and

Correlation & Price change

A.I.dvisor indicates that over the last year, GTBP has been loosely correlated with BDRX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if GTBP jumps, then BDRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GTBP
1D Price
Change %
GTBP100%
N/A
BDRX - GTBP
39%
Loosely correlated
-6.21%
SLGL - GTBP
34%
Loosely correlated
-0.81%
RAPT - GTBP
33%
Loosely correlated
-13.36%
TRAW - GTBP
31%
Poorly correlated
N/A
PTCT - GTBP
28%
Poorly correlated
+0.59%
More